UNSPSC 51371603: Alfametadol or alphamethadol

This classification denotes an analgesic agent with the molecular formula C21H29NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XBD99QNI42, chemically known as 6-dimethylamino-4,4-diphenyl-3-heptanol, hydrochloride but generally known as alphamethadol, which bears US NIH Compound Identifier 28397. European Medicines Agency schedules Alphamethadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05365MIG. The term ALPHAMETHADOL is an International Non-Proprietary Name.

ALPHAMETHADOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Alfametadol or alphamethadol bears US NLM identifiers UMLS ID C2346722 and NCI Concept Code C72135. SMILES: OC(C(CC(N(C)C)C)(C1CCCCC1)C1CCCCC1)CC.

UNSPSC 51371603 Alfametadol or alphamethadol is a Commodity code that nominally covers synthetic opioid pharmaceutical products, but the recent state and local solicitations tagged under this code show minimal alignment with the code's intended scope. The three opportunities posted between January and June 2026 center on naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products — none of which are alfametadol or alphamethadol specifically. State and local issuing bodies appear to be using this code as a catch-all classification for pharmaceutical sourcing and opioid-related public health initiatives rather than for procurement of this specific drug. The mix of buyers includes county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota, Oregon, and other participants).

Activity spans Florida, Texas, and the MMCAP multistate region. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2026, under a two-year contract with optional one-year renewal. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, gathering vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program with no formal award value. MMCAP released RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with a March 26, 2026, response deadline and an effective date of July 1, 2026. The code shows little recent relevant activity for alfametadol or alphamethadol as specifically named products.